Author

Marc Ferrante

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Marc Ferrante  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Marc Ferrante  et al.

MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS
MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS

Marc Ferrante  et al.

DISEASE ACCEPTANCE, BUT NOT PERCEIVED CONTROL, IS UNIQUELY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE-RELATED DISABILITY
DISEASE ACCEPTANCE, BUT NOT PERCEIVED CONTROL, IS UNIQUELY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE-RELATED DISABILITY

Marc Ferrante  et al.

EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS
EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS

Marc Ferrante  et al.

LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT
LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT

Marc Ferrante  et al.

COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

Marc Ferrante  et al.

COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS

Marc Ferrante  et al.

DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE
DEVELOPMENT OF A CORE OUTCOME SET FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE THROUGH AN INTERNATIONAL MULTI-STAKEHOLDER DELPHI EXERCISE

Marc Ferrante  et al.

VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS
VEDOLIZUMAB IS ASSOCIATED WITH STEROID-FREE CLINICAL REMISSION AND DISCONTINUATION-FREE SURVIVAL IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE PROCTITIS

Marc Ferrante  et al.

Item 21 - 30 / 30
1
2